DarioHealth (NASDAQ:DRIO – Get Free Report) will likely be posting its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect DarioHealth to post earnings of ($0.51) per share and revenue of $5.21 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.
DarioHealth (NASDAQ:DRIO – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.37. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. The business had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.92 million. On average, analysts expect DarioHealth to post ($2.94) EPS for the current fiscal year and ($2.17) EPS for the next fiscal year.
DarioHealth Trading Down 13.4%
Shares of DarioHealth stock opened at $2.06 on Tuesday. DarioHealth has a fifty-two week low of $1.93 and a fifty-two week high of $14.77. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.92 and a current ratio of 2.31. The company’s 50 day moving average price is $5.46 and its two-hundred day moving average price is $7.51.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Alliance Global Partners initiated coverage on shares of DarioHealth in a report on Wednesday, August 19th. They set a “buy” rating and a $12.00 price target for the company. TD Cowen cut their price objective on DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, August 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a report on Tuesday, October 6th. Finally, BTIG Research assumed coverage on DarioHealth in a research report on Tuesday, October 27th. They set a “buy” rating and a $6.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, DarioHealth presently has a consensus rating of “Hold” and an average price target of $9.00.
Get Our Latest Analysis on DarioHealth
DarioHealth Company Profile
DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health.
The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.
Read More
- Five stocks we like better than DarioHealth
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.
